Gingival Crevicular Fluid, Salivary, and Serum Biomarkers Levels in Periodontal Treatment
NCT ID: NCT05395455
Last Updated: 2022-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
75 participants
INTERVENTIONAL
2018-11-12
2020-01-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Periodontal Therapy on Biomarkers in Periodontitis
NCT05005923
Salivary Proteome in Response to Non-surgical Periodontal Treatment
NCT05952895
Effect of Non-Surgical Periodontal Treatment on Gingival Crevicular Fluid and Serum Biomarker Levels
NCT06175624
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases
NCT06075680
Effect of Periodontal Treatment on Salivary and Serum Biomarkers in Periodontitis
NCT06255470
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
IL-6, a pro-inflammatory cytokine and is one of the important molecules in the regulation of inflammatory immune responses in periodontitis. IL-10, an anti-inflammatory cytokine, affects monocytes and macrophages and their immune mediator release.
This study is the first controlled clinical study that examines the levels of IL-26 in GCF, saliva, and serum in two different periodontitis, and evaluates the situation before and after the treatment. The first hypothesis of this study GCF, salivary, and serum IL-26 and IL-6 levels will be high and GCF, salivary and serum IL-10 will be low in periodontitis groups, in contrast to the periodontal health the second hypothesis of this study is that after periodontal treatment, GCF, saliva, and serum IL-26 and IL-6 will decrease and GCF, saliva, and serum IL-10 will increase.
Based on these hypotheses, the aim of the study is; to compare the levels of IL-26, IL-6, and IL-10 in GCF, saliva, and serum of healthy controls, SIII-GB-P, and SIII-GC-P subjects and to evaluate the effect of periodontal treatment.
A total of 75 systemically healthy patients; 25 periodontally healthy, 25 SIII-GB-P, and 25 SIII-GC-P were included in this study. The clinical periodontal examination, including measurement of probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI), and plaque index (PI) was performed at 6 sites per tooth, except the third molars. The presence of alveolar bone loss was assessed on the digital panoramic radiograph in each participant, which was supplemented with periapical radiographs if necessary.
The periodontal status of each patient was evaluated by a single calibrated periodontist with a manual probe. The diagnosis of periodontitis or periodontally health was determined according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Periodontally healthy individuals (n=25) in the control group had no sites with PD \>3 mm and CAL \>2 mm and also no radiographic evidence of alveolar bone loss. BOP was \<10% in the whole mouth and exhibited no history of periodontitis. The periodontitis stage III patients had a minimum of 3 teeth apart from the first molars and incisors showing CAL ≥5 mm and PD ≥6 mm and showed no\>4 teeth loss caused by periodontitis. The radiographic bone loss extends from coronal to middle third or beyond. Radiographic bone loss was determined from the tooth showing the most severe bone loss as a percentage of root length. If the values of bone loss %/age were between 0.25 and 1.0, the patients were assigned to grade B (n=25). If higher than 1.0, the patients were assigned to grade C (n=25).
Treatment The periodontitis patients received conventional scaling and root planning (SRP) under local anesthesia in a total of 4 sessions in two weeks. SRP was performed by the same periodontist using ultrasonic inserts and manual periodontal curettes. Re-evaluations were performed at 1 and 3 months following the completion of the treatment.
GCF, Saliva and Serum Sampling Filter paper strips were used to collect GCF samples. In the healthy control group, GCF was collected from the interproximal sites of single-rooted and multiple rooted teeth from each quadrant. GCF was collected from the sites with PD ≥ 6 mm and radiographic bone loss in periodontitis groups. Selected sites were isolated with cotton rolls. The paper strip was removed after 30 sec after inserting the periodontal pocket. A total of 5 mL of unstimulated whole saliva was collected by the passive drool method in the morning. The saliva was collected over a period of 5 minutes with instructions to pool saliva on the floor of the mouth and passively drool it into a sterile glass beaker and samples are immediately transferred to a 2 mL polypropylene tube. A total of 5 mL of blood was collected from the antecubital fossa by venepuncture method. Serum was isolated from the blood by centrifuging at 5000 rpm for 10 minutes followed by its rapid transfer to a sterile polypropylene tube. All the samples were stored at -80°C.
Biomarker Immunoassays GCF, saliva, and serum samples were thawed on ice. The saliva samples were centrifuged at 5.000 rpm for 15 minutes at room temperature, and supernatants were immediately used for assays. GCF, serum, and salivary samples of IL-26, IL-10, and IL-6 were measured by ELISA using commercial kits.
Statistical Analysis All statistical analyses were carried out with the standard statistical software package. For the intra-group comparisons, if the data were not normally disturbed, the Friedman test and the Dunn test with the Bonferroni correction were used to analyze the change between baseline and 1 month and 3 months after treatment. For inter-group comparisons, the Mann-Whitney U test was performed. The Spearman's rank correlation test was used to detect the correlations of biochemical parameters with clinical parameters and each other in periodontitis group before and after treatment. All tests were performed at a significance level of p\<0.05.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Periodontally Healthy
Systemically and periodontally healthy
No interventions assigned to this group
Stage III Grade B Periodontitis
The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
Non-surgical periodontal treatment
Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
Stage III Grade C Periodontitis
The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
Non-surgical periodontal treatment
Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-surgical periodontal treatment
Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* having ≥20 teeth present (except third molars)
* individuals with periodontally healthy, stage III grade B and C periodontitis diagnoses
Exclusion Criteria
* usage of antibiotics, non-steroidal anti-inflammatory drugs, and immunosuppressive agents within the past 6 months
* having any non-inflammatory destructive periodontal disease
* non-surgical/surgical periodontal therapy received in the past year
* pregnant/ lactating/ postmenopausal females
30 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marmara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hatice Selin Yıldırım
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAG-C-DRP-241018-0575
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.